Neurotransplantation: the time has come?

Cover Page

Cite item

Full Text


Problems in curing disorders of the brain are caused by several characteristic features of the nervous tissue, such as postmitotic nature of neurons, their limited reparative potential, significant energy dependence, etc. Because of special vulnerability and extremely high specialization, neurons are very sensitive to the action of any pathological factors, while existing possibilities of their trophic and metabolic support are scanty. Therefore, the creation of new reparative strategies, including substitutive cell technologies, is immediate task in neurology. Neurodegenerative disorders, Parkinson’s disease (PD), Huntington’s disease and others, are an “ideal” model for elaborating such strategies. As main motor symptoms of PD are related to degeneration of the dopaminergic nigrostriatal pathway, treatment of these patients, theoretically, may be based on transplantation of dopamine-producing neurons into the striatum. In the paper, analyzed are the results of many-year experimental (on models of parkinsonism) and preliminary clinical trials of neurotransplantation with the use of fetal tissues (dopaminergic cells of the ventral midbrain) and dopaminergic neurons differentiated from embryonal stem cells and induced pluripotent. Newest scientific achievements in this field, improvement of cell protocols and successful resolving of a number of technical and medical problems allow saying that neurotransplantation becomes clinical reality just before our eyes.

About the authors

Sergey N. Illarioshkin

Research Center of Neurology

Author for correspondence.
Russian Federation, Moscow


  1. Viktorov I.V., Savchenko E.A., Ukhova O.V. et al. [Multipotent stem cells and progenitor cells of the olfactory epithelium]. Kletochnyye tekhnologii v biologii i meditsine 2006; 4: 185–193. (In Russ.)
  2. Illarioshkin S.N., Khaspekov L.G., Grivennikov I.A. Modelirovaniye bolezni Parkinsona s ispol’zovaniyem indutsirovannykh plyuripotentnykh stvolovykh kletok. [Modeling of Parkinson’s disease with the use of induced pluripotent stem cells] Moscow: Sovero-press, 2016. 183 p. (In Russ.)
  3. Lebedeva O.S., Lagar’kova M.A., Kiselev S.L. et al. [Morphofunctional properties of induced pluripotent stem cells derived from human skin fibroblasts and differentiated into dopaminergic neurons]. Neyrokhimiya 2013; 3: 233–241.(In Russ.)
  4. Stavrovskaya A.V., Voronkov D.N., Yamshchikova N.G. et al. [Morphochemical evaluation of the results of neurotransplantation in experimental parkinsonism]. Annals of Clinical and Experimental Neurology 2015; 2: 28–32. (In Russ.)
  5. Stavrovskaya A.V., Yamshchikova N.G., Ol’shansky А.S. et al. [Transplantation of neuronal precursors obtained from induced pluripotent stem cells in the striatum of rats with a toxic model of Huntington’s disease]. Annals of Clinical and Experimental Neurology 2016; 4: 39–44. (in Russ.)
  6. Khaspekov L.G., Stavrovskaya A.V., Khudoyerkov R.M. et al. [Experimental aspects of the study of dopaminergic neurons obtained from human skin fibroblasts with the technology of induced pluripotent stem cells]. In: [S.N. Illarioshkin, O.S. Levin (Eds.) Parkinson’s Disease and Movement Disorders]. Moscow:Sovero-press, 2014: 49–55. (In Russ.)
  7. Shtok V.N., Ugryumov M.V., Fedorova N.V. et al. [Neurotransplantation in the treatment of Parkinson’s disease (follow-up study)]. Zhurnal voprosy neyrokhirurgii im. N.N.Burdenko 2002; 2: 29–33. (In Russ.)
  8. Avaliani N., Sørensen A.T., Ledri M. et al. Optogenetics reveal delayed afferent synaptogenesis on grafted human-induced pluripotent stem cell-derived neural progenitors. Stem Cells 2014; 32: 3088–3098. doi: 10.1002/stem.1823. PMID: 25183299.
  9. Bakay R.A., Fiandaca M.S., Barrow D.L. et al. Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. Appl Neurophysiol 1985; 48: 358–361. PMID: 3879797.
  10. Barker R.A., Parmar M., Kirkeby A. et al. Are stem cell-based therapies for Parkinson’s disease ready for the clinic in 2016? J Parkinsons Dis 2016; 6: 57–63.
  11. doi: 10.3233/JPD-160798. PMID: 27003785.
  12. Bjorklund A., Kordower J.H. Cell therapy for Parkinson’s disease: what next? Mov Disord 2013; 28: 110–115. doi: 10.1002/mds.25343. PMID: 23390097.
  13. Bjorklund A., Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177: 555–560. PMID:
  14. Brundin P., Kordower J.H. Neuropathology in transplants in Parkinson’s disease:
  15. implications for disease pathogenesis and the future of cell therapy. Prog Brain Res 2012; 200: 221–241. doi: 10.1016/B978-0-444-59575-1.00010-7. PMID: 23195421.
  16. Brundin P., Strecker R.E., Lindvall O. et al. Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson’s disease. Ann NY Acad Sci 1987; 495: 473–496. PMID: 3474955.
  17. Brundin P., Strecker R.E., Widner H. et al. Human fetal dopamine neurons grafted in a rat model of Parkinson’s disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1988; 70: 192–208. PMID: 3402564.
  18. Cai J., Yang M., Poremsky E. et al. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev 2010; 19: 1017–1023. doi: 10.1089/scd.2009.0319. PMID: 19824823.
  19. Caiazzo M., Dell’Anno M.T., Dvoretskova E. et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011; 476: 224–227. doi: 10.1038/nature10284. PMID: 2172532.
  20. Carta M., Carlsson T., Munoz A. et al. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson’s disease. Mov Disord 2010; 25: S174–S179. doi: 10.1002/mds.22792. PMID: 20187238.
  21. Chang Y.L., Chen S.J., Kao C.L. et al. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology. Cell Transplant 2012; 21:313–332. doi: 10.3727/096368911X580572. PMID: 21669041.
  22. Clarke D.J., Brundin P., Strecker R.E. et al. Human fetal dopamine neurons grafted in a rat model of Parkinson’s disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res 1988; 73: 115–126. PMID: 3145209.
  23. Dell’Anno M.T., Caiazzo M., Leo D. et al. Remote control of induced dopaminergic neurons in parkinsonian rats. J Clin Invest 2014; 124: 3215–3229. doi: 10.1172/JCI74664. PMID: 24937431.
  24. Demuth H.-U., Dijkhuizen R.M., Farr T.D. et al. Recent progress in translational research on neurovascular and neurodegenerative disorders. Restor Neurol Neurosci 2017; 35: 87–103. doi: 10.3233/RNN-160690. PMID: 28059802.
  25. Doi D., Samata B., Katsukawa M. et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2014; 2: 337–350. doi: 10.1016/j.stemcr.2014.01.013. PMID: 24672756.
  26. Freed C.R., Greene P.E., Breeze R.E. et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. N Engl J Med 2001; 344: 710–719. doi: 10.1056/NEJM200103083441002. PMID: 11236774.
  27. Fundamental neuroscience (eds. L. Squire, D. Berg, Bloom F. et al.). 3d ed. Academic Press, 2008.
  28. Goetz C.G., Stebbins G.T., Klawans H.L. et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology 1991; 41: 1719–1722. PMID: 1944898.
  29. Gross R.E., Watts R.L., Hauser R.A. et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2011; 10: 509–519. doi: 10.1016/S1474-4422(11)70097-7. PMID: 21565557.
  30. Hagell P., Piccini P., Bjorklund A. et al. Dyskinesias following neural transplantation in Parkinson’s disease. Nature Neurosci 2002; 5: 627–628. doi: 10.1038/nn863. PMID: 12042822.
  31. Hallett P.J., Deleidi M., Astradsson A. et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell 2015; 16: 269–274. doi: 10.1016/j.stem.2015.01.018. PMID: 25732245.
  32. Hargus G., Cooper O., Deleidi M. et al. Differentiated Parkinson patient-derived induced pluripotent cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 2010; 107: 15921–15926. doi: 10.1073/pnas.1010209107. PMID: 20798034.
  33. Kauhausen J.A., Thompson L.H., Parish C.L. Chondroitinase improves midbrain pathway reconstruction by transplanted dopamine progenitors in Parkinsonian mice. Mol Cell Neurosci 2015; 69: 22–29. doi: 10.1016/j.mcn.2015.10.002. PMID: 26463051.
  34. Kefalopoulou Z., Politis M., Piccini P. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 2014; 71: 83–87. doi: 10.1001/jamaneurol.2013.4749. PMID: 24217017.
  35. Kikuchi T., Morizane A., Doi D. et al. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson’s disease. J Parkinsons Dis 2011; 1: 395–412. doi: 10.3233/JPD-2011-11070. PMID: 23933658.
  36. Kikuchi T., Morizane A., Doi D. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature 2017; 548: 592–596. doi: 10.1038/nature23664. PMID: 28858313.
  37. Kim D., Kim C.H., Moon J.I. et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4: 472–476. doi: 10.1016/j.stem.2009.05.005. PMID: 19481515.
  38. Kimmelman J., Heslop H.E., Sugarman J. et al. New ISSCR guidelines: clinical translation of stem cell research. Lancet 2016; 387: 1979–1981. doi: 10.1016/S0140-6736(16)30390-7. PMID: 27179752.
  39. Lane E.L., Vercammen L., Cenci M.A., Brundin P. Priming for L-DOPA- induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats. Exp Neurol 2009; 219: 355–358. doi: 10.1016/j.expneurol.2009.04.010. PMID: 19393238.
  40. Lindvall O. Treatment of Parkinson’s disease using cell transplantation. Philos Trans R Soc Lond B Biol Sci 2015; 370: 20140370. doi: 10.1098/rstb.2014.0370.PMID: 26416681.
  41. Lindvall O. Clinical translation of stem cell transplantation in Parkinson’s disease. J Intern Med 2016; 279: 30–40. doi: 10.1111/joim.12415. PMID: 26332959.
  42. Lindvall O., Sawle G., Widner H. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease. Ann Neurol 1994; 35: 172–180. doi: 10.1002/ana.410350208. PMID: 8109898.
  43. Mínguez-Castellanos A., Escamilla-Sevilla F., Hotton G.R. et al. Carotid body autotransplantation in Parkinson disease: a clinical anSSCRd positron emission tomography study. J Neurol Neurosurg Psychiatry 2007; 78: 825–831. doi: 10.1136/jnnp.2006.106021. PMID: 17220289.
  44. Morizane A., Doi D., Kikuchi T. et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports 2013; 1: 283–292. doi: 10.1016/j.stemcr. 2013.08.007. PMID: 24319664.
  45. Neal E.G., Liska M.G., Lippert T. et al. An update on intracerebral stem cell grafts. Expert Rev Neurother 2018; 18: 557–572. doi: 10.1080/14737175.2018.1491309. PMID: 29961357.
  46. Nishimura K., Murayama S., Takahashi J. Identification of neurexophilin 3 as a novel supportive factor for survival of induced pluripotent stem cell-derived dopaminergic progenitors. Stem Cells Transl Med 2015; 4: 932–944. doi: 10.5966/sctm.2014-0197. PMID: 26041738.
  47. Okita K., Matsumura Y., Sato Y. et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011; 8: 409–412. doi: 10.1038/nmeth.1591. PMID: 21460823.
  48. Olanow C.W., Goetz C.G., Kordower J.H. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003; 54: 403–414. doi: 10.1002/ana.10720. PMID: 12953276.
  49. Olanow C.W., Isacson O. Stem cells for Parkinson’s disease: advancing science but protecting patients. Mov Disord 2012; 27: 1475–1477. doi: 10.1002/mds.25170. PMID: 23032987.
  50. Olanow C.W., Schapira A.H. Therapeutic prospects for Parkinson disease. Ann Neurol 2013; 74: 337–347. doi: 10.1002/ana.24011. PMID: 2403834.
  51. Park Y.S., Lee J.W., Kwon H.B., Kwak K.A. Current perspectives regarding stem cell-based therapy for ischemic stroke. Curr Pharm Des 2018. doi: 10.2174/1381612824666180604111806. PMID: 29866000 [Epub ahead of print].
  52. Petit G.H., Olsson T.T., Brundin P. The future of cell therapies and brainrepair: Parkinson’s disease leads the way. Neuropathol Appl Neurobiol 2014; 40: 60–70. doi: 10.1111/nan.12110. PMID: 24372386.
  53. Poewe W., Seppi K., Tanner C.M. et al. Parkinson’s disease. Nat Rev Dis Primers 2017; 3: 17013. doi: 10.1038/nrdp.2017.13. PMID: 28332488.
  54. Rhee Y.H., Ko J.Y., Chang M.Y. et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest 2011; 121: 2326–2335. doi: 10.1172/JCI45794. PMID: 21576821.
  55. Spencer D.D., Robbins R.J., Naftolin F. et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease. N Engl J Med 1992; 327: 1541–1548. doi: 10.1056/NEJM199211263272201. PMID: 1435880.
  56. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663–676. doi: 10.1016/j.cell.2006.07.024. PMID: 16904174.
  57. Wernig M., Zhao J.P., Pruszak J. et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease. Proc Natl Acad Sci USA 2008; 105: 5856–5861.doi: 10.1073/pnas.0801677105. PMID: 18391196.

Supplementary files

Supplementary Files

Copyright (c) 2018 Illarioshkin S.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies